Case report

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series

Michelle A Lowes¹ , Francesca Chamian¹ , Maria V Abello¹ , Craig Leonardi² , Wolfgang Dummer³ , Kim Papp⁴ and James G Krueger¹

¹  Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA

²  Central Dermatology, St Louis, Missouri, USA

³  Genentech Inc., San Francisco, California, USA

⁴  Probity Medical Research, Waterloo, Canada

author email corresponding author email

BMC Dermatology 2007, 7:2doi:10.1186/1471-5945-7-2

Published:	26 February 2007

Abstract

Background

Newer biological therapies for moderate-to-severe psoriasis are being used more frequently, but unexpected effects may occur.

Case presentations

We present a group of 15 patients who developed inflammatory papules while on efalizumab therapy (Raptiva, Genentech Inc, anti-CD11a). Immunohistochemistry showed that there were increased CD11b⁺, CD11c⁺ and iNOS⁺ cells (myeloid leukocytes) in the papules, with relatively few CD3⁺ T cells. While efalizumab caused a decreased expression of CD11a on T cells, other circulating leukocytes from patients receiving this therapy often showed increased CD11b and CD11c. In the setting of an additional stimulus such as skin trauma, this may predispose to increased trafficking into the skin using these alternative β2 integrins. In addition, there may be impaired immune synapse formation, limiting the development of these lesions to small papules. There is little evidence for these papular lesions being "allergic" in nature as there are few eosinophils on biopsy, and they respond to minimal or no therapy even if efalizumab is continued.

Conclusion

We hypothesize that these papules may represent a unique type of "mechanistic" inflammatory reaction, seen only in the context of drug-induced CD11a blockade, and not during the natural disease process.